Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Temporal expression of galectin-3 following myocardial infarction.

Milner TD, Viner AC, MacKinnon AC, Sethi T, Flapan AD.

Acta Cardiol. 2014 Dec;69(6):595-602.

PMID:
25643429
2.

Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study.

George M, Shanmugam E, Srivatsan V, Vasanth K, Ramraj B, Rajaram M, Jena A, Sridhar A, Chaudhury M, Kaliappan I.

Ther Adv Cardiovasc Dis. 2015 Oct;9(5):275-84. doi: 10.1177/1753944715578405. Epub 2015 Mar 25.

PMID:
25814534
3.

Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.

Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, Ko SF, Yip HK.

J Atheroscler Thromb. 2012;19(12):1073-82. Epub 2012 Oct 3.

4.

High-sensitivity troponin T for prediction of left ventricular function and infarct size one year following ST-elevation myocardial infarction.

Reinstadler SJ, Feistritzer HJ, Klug G, Mair J, Tu AM, Kofler M, Henninger B, Franz WM, Metzler B.

Int J Cardiol. 2016 Jan 1;202:188-93. doi: 10.1016/j.ijcard.2015.09.001. Epub 2015 Sep 6.

PMID:
26397408
5.

High-sensitivity troponin T predicts infarct scar characteristics and adverse left ventricular function by cardiac magnetic resonance imaging early after reperfused acute myocardial infarction.

Nguyen TL, Phan JA, Hee L, Moses DA, Otton J, Terreblanche OD, Xiong J, Premawardhana U, Rajaratnam R, Juergens CP, Dimitri HR, French JK, Richards DA, Thomas L.

Am Heart J. 2015 Oct;170(4):715-725.e2. doi: 10.1016/j.ahj.2015.06.022. Epub 2015 Jul 2.

PMID:
26386795
6.

Osteoprotegerin levels change during STEMI and reflect cardiac function.

Lindberg S, Jensen JS, Hoffmann S, Iversen AZ, Pedersen SH, Mogelvang R, Galatius S, Flyvbjerg A, Bjerre M.

Can J Cardiol. 2014 Dec;30(12):1523-8. doi: 10.1016/j.cjca.2014.08.015. Epub 2014 Aug 23.

PMID:
25475457
7.

Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction.

van der Velde AR, Lexis CP, Meijers WC, van der Horst IC, Lipsic E, Dokter MM, van Veldhuisen DJ, van der Harst P, de Boer RA.

Clin Chim Acta. 2016 Jan 15;452:50-7. doi: 10.1016/j.cca.2015.10.034. Epub 2015 Oct 31.

PMID:
26528636
8.

Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.

Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, Lubnow M, Müller T, Muders F, Holmer S, Riegger GA, Luchner A.

Clin Chem Lab Med. 2010 Jun;48(6):875-81. doi: 10.1515/CCLM.2010.164.

PMID:
20441480
9.
10.

Association between discharge heart rate and left ventricular adverse remodelling in ST segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.

Joyce E, Hoogslag GE, Leong DP, Fox K, Schalij MJ, Marsan NA, Bax JJ, Delgado V.

Heart. 2013 Apr;99(8):556-61. doi: 10.1136/heartjnl-2012-303406. Epub 2013 Mar 6.

PMID:
23468514
11.

Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, Mancha F, Sanchez A, Rodriguez-Puras MJ, Villa M, Lopez-Pardo F, Diaz de la Llera L, Valle JI, Martinez A.

Heart. 2012 Aug;98(15):1153-9. doi: 10.1136/heartjnl-2012-301636. Epub 2012 May 9.

PMID:
22572051
12.
13.
14.

Myocardial tissue perfusion predicts the evolution of fragmented QRS in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Ozcan F, Turak O, Canpolat U, Kadife I, Avci S, Işleyen A, Cebeci M, Malçok Gürel Ö, Başar FN, Tok D, Topaloğlu S, Aras D, Aydoğdu S.

Ann Noninvasive Electrocardiol. 2014 Sep;19(5):454-61. doi: 10.1111/anec.12146. Epub 2014 Mar 4.

PMID:
24589234
15.

Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Hall TS, Hallén J, Krucoff MW, Roe MT, Brennan DM, Agewall S, Atar D, Lincoff AM.

Am Heart J. 2015 Feb;169(2):257-265.e1. doi: 10.1016/j.ahj.2014.10.015. Epub 2014 Nov 4.

PMID:
25641535
16.

Long-Term Outcomes in Survivors of Early Ventricular Arrhythmias After Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention.

Liang JJ, Fender EA, Cha YM, Lennon RJ, Prasad A, Barsness GW.

Am J Cardiol. 2016 Mar 1;117(5):709-13. doi: 10.1016/j.amjcard.2015.12.002. Epub 2015 Dec 13.

PMID:
26796195
17.
18.

B-type natriuretic peptide as a predictor of ischemia/reperfusion injury immediately after myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction.

Arakawa K, Himeno H, Kirigaya J, Otomo F, Matsushita K, Nakahashi H, Shimizu S, Nitta M, Takamizawa T, Yano H, Endo M, Kanna M, Kimura K, Umemura S.

Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):62-70. doi: 10.1177/2048872615568964. Epub 2015 Jan 21.

PMID:
25609593
19.

[Evaluation of plasma renin activity in acute myocardial infarction patients treated with primary percutaneous coronary interventions].

Stryjewski PJ, Pietrucha AZ, Stopyra K, Nessler B, Kruszelnicka O, Gackowski A, Konduracka E, Sztefko K, Badacz L, Nessler J.

Przegl Lek. 2011;68(7):354-8. Polish.

PMID:
22010471
20.

Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time.

Suades R, Padró T, Crespo J, Ramaiola I, Martin-Yuste V, Sabaté M, Sans-Roselló J, Sionis A, Badimon L.

Int J Cardiol. 2016 Jan 1;202:378-87. doi: 10.1016/j.ijcard.2015.09.011. Epub 2015 Sep 12.

PMID:
26432487

Supplemental Content

Support Center